- The authors' reply: Use of erythropoiesis-stimulating agents in obese hemodialysis patients
-
El-Kannishy GM
- KMID: 2447174
- Kidney Res Clin Pract.
- 2018 Sep;37(3):310-311.
- doi: 10.23876/j.krcp.2018.37.3.310
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Obesity may be erythropoietin dose-saving in hemodialysis patients
-
El-Kannishy GM, Megahed AF, Tawfik MM, El-Said G, Zakaria RT, Mohamed NA, Taha EM, Ammar AA, Abd Eltawab AM, Sayed-Ahmed NA
- KMID: 2416083
- Kidney Res Clin Pract.
- 2018 Jun;37(2):148-156.
- doi: 10.23876/j.krcp.2018.37.2.148
BACKGROUND: In dialysis patients, the obesity-survival paradox still requires an explanation. Anemia and high doses of erythropoiesis-stimulating agents (ESAs) are associated with worse outcomes in the hemodialysis (HD) population. In... -
- CITED
-
- Close
- SHARE
-
- Close
